Literature DB >> 7048100

Cryptococcal capsular polysaccharide clearance in nonimmune mice.

H G Muchmore, E N Scott, F G Felton, R A Fromtling.   

Abstract

Clearance of cryptococcal polysaccharide (CP) from tissues and body fluids of nonimmune mice was studied. Mice were injected intravenously only with one mg of purified CP, and serum, urine and tissues were obtained from each animal at various intervals for a period of 84 days. Tissue extracts, serum and urine were tested for CP content by enzyme-linked immunosorbent assay (ELISA) and latex agglutination. High concentrations of CP were detected by both assays one-half hour after injection in blood (serum), liver, spleen, kidney and lung (extracts). The duration of ELISA detectable CP was longest (70 days) in liver and spleen and shortest (14 days) in lung extract. By 14 days after injection, concentration of CP in the blood fell below that found in the liver and spleen. CP remained detectable (titers 32-64) after all other extracts became negative. These results indicate that CP is stored in tissues (binding mechanism and site unknown), and that the liver and spleen possess greater storage capacity than other tissues. Antibody (IgM) to CP appeared in low titer on the 14th day and thereafter.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7048100     DOI: 10.1007/bf00436580

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  14 in total

1.  DETECTION OF CRYPTOCOCCUS NEOFORMANS ANTIGEN IN BODY FLUIDS BY LATEX PARTICLE AGGLUTINATION.

Authors:  N BLOOMFIELD; M A GORDON; D F ELMENDORF
Journal:  Proc Soc Exp Biol Med       Date:  1963-10

2.  DETECTION OF CRYPTOCOCCAL POLYSACCHARIDE IN SERUM AND SPINAL FLUID: VALUE IN DIAGNOSIS AND PROGNOSIS.

Authors:  J E BENNETT; H F HASENCLEVER; B S TYNES
Journal:  Trans Assoc Am Physicians       Date:  1964

3.  CRYPTOCOCCUS NEOFORMANS POLYSACCHARIDE: STUDIES OF SEROLOGIC PROPERTIES AND ROLE IN INFECTION.

Authors:  J E BENNETT; H F HASENCLEVER
Journal:  J Immunol       Date:  1965-06       Impact factor: 5.422

4.  Induction of humoral antibody response by soluble polysaccharide of Cryptococcus neoformans.

Authors:  T R Kozel; J Cazin
Journal:  Mycopathol Mycol Appl       Date:  1974-10-15

5.  Coupling of enzymes to proteins with glutaraldehyde. Use of the conjugates for the detection of antigens and antibodies.

Authors:  S Avrameas
Journal:  Immunochemistry       Date:  1969-01

6.  Comparison of enzyme immunoassay and latex agglutination methods for detection of Cryptococcus neoformans antigen.

Authors:  E N Scott; H G Muchmore; F G Felton
Journal:  Am J Clin Pathol       Date:  1980-06       Impact factor: 2.493

7.  Cryptococcus neoformans. 3. Inhibition of phagocytosis.

Authors:  G S Bulmer; M D Sans
Journal:  J Bacteriol       Date:  1968-01       Impact factor: 3.490

8.  Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness.

Authors:  T R Kozel; W F Gulley; J Cazin
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

9.  Intracellular fate of Cryptococcus neoformans.

Authors:  J R Tacker; F Farhi; G S Bulmer
Journal:  Infect Immun       Date:  1972-08       Impact factor: 3.441

10.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  9 in total

1.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.

Authors:  Lauren E Yauch; Michael K Mansour; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis.

Authors:  Luciana Tissi; Manuela Puliti; Francesco Bistoni; Paolo Mosci; Thomas R Kozel; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan.

Authors:  Laura S Chiapello; José L Baronetti; María P Aoki; Susana Gea; Héctor Rubinstein; Diana T Masih
Journal:  Immunology       Date:  2004-11       Impact factor: 7.397

Review 5.  Immunity in cryptococcosis: an overview.

Authors:  R A Fromtling; H J Shadomy
Journal:  Mycopathologia       Date:  1982-03-19       Impact factor: 2.574

6.  Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody.

Authors:  D L Goldman; S C Lee; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis.

Authors:  S C Lee; A Casadevall; D W Dickson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

8.  Spleen deposition of Cryptococcus neoformans capsular glucuronoxylomannan in rodents occurs in red pulp macrophages and not marginal zone macrophages expressing the C-type lectin SIGN-R1.

Authors:  Magdia De Jesus; Chae Gyu Park; Ya Su; David L Goldman; Ralph M Steinman; Arturo Casadevall
Journal:  Med Mycol       Date:  2008-03       Impact factor: 4.076

9.  Biology and function of exo-polysaccharides from human fungal pathogens.

Authors:  Krystal Y Chung; Jessica C S Brown
Journal:  Curr Clin Microbiol Rep       Date:  2020-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.